Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.
作者信息
Kahana Alon, Worden Francis P, Elner Victor M
机构信息
Eye Plastic and Orbital Surgery Service, Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor.
出版信息
JAMA Ophthalmol. 2013 Oct;131(10):1364-6. doi: 10.1001/jamaophthalmol.2013.4430.
Abstract
摘要
相似文献
1
Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.维莫德吉作为眼眶基底细胞癌的保眼辅助治疗药物。
JAMA Ophthalmol. 2013 Oct;131(10):1364-6. doi: 10.1001/jamaophthalmol.2013.4430.
2
Vismodegib for periocular and orbital basal cell carcinoma.维莫德吉治疗眼周和眼眶基底细胞癌。
JAMA Ophthalmol. 2013 Dec;131(12):1591-4. doi: 10.1001/jamaophthalmol.2013.5018.
3
Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.口服 Hedgehog 信号通路抑制作为局部晚期眼眶基底细胞癌眼部挽救治疗的一种手段
Dermatol Surg. 2019 Jan;45(1):17-25. doi: 10.1097/DSS.0000000000001640.
4
Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.维莫德吉（Erivedge）治疗累及眼眶及眼周区域的基底细胞癌的疗效
Ophthalmic Plast Reconstr Surg. 2015 Nov-Dec;31(6):463-6. doi: 10.1097/IOP.0000000000000388.
5
Vismodegib (Erivedge) for basal cell carcinoma.维莫德吉（Erivedge）用于治疗基底细胞癌。
Med Lett Drugs Ther. 2012 Jul 9;54(1394):53-4.
6
Indications and limitations of vismodegib for basal cell carcinoma.维莫德吉用于基底细胞癌的适应证及局限性
JAMA Ophthalmol. 2014 Jul;132(7):905-6. doi: 10.1001/jamaophthalmol.2014.1787.
7
Indications and limitations of vismodegib for basal cell carcinoma--reply.维莫德吉用于基底细胞癌的适应证及局限性——答复
JAMA Ophthalmol. 2014 Jul;132(7):906. doi: 10.1001/jamaophthalmol.2014.1805.
8
Vismodegib in advanced basal-cell carcinoma.维莫德吉用于晚期基底细胞癌
N Engl J Med. 2012 Sep 6;367(10):969-70; author reply 970. doi: 10.1056/NEJMc1208003.
9
Vismodegib in advanced basal-cell carcinoma.维莫德吉用于晚期基底细胞癌
N Engl J Med. 2012 Sep 6;367(10):970; author reply 970-1. doi: 10.1056/NEJMc1208003.
10
Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.维莫德吉治疗后浸润脑的基底细胞癌消退
J Dtsch Dermatol Ges. 2014 Oct;12(10):906-7. doi: 10.1111/ddg.12342. Epub 2014 Jul 17.
引用本文的文献
1
Vismodegib as an adjuvant treatment for periorbital basal cell carcinoma: a case report and review of literature.维莫德吉作为眶周基底细胞癌的辅助治疗：一例病例报告及文献综述
Ann Transl Med. 2024 Jun 10;12(3):54. doi: 10.21037/atm-23-1589. Epub 2024 Jan 11.
2
Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances.伴有眼眶侵犯的晚期眼周基底细胞癌：治疗与进展的最新情况
J Ophthalmol. 2024 Feb 29;2024:4347707. doi: 10.1155/2024/4347707. eCollection 2024.
3
Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial.分析眼周基底细胞癌在 Hedgehog 通路抑制后的残留病变：VISORB 试验的随访。
PLoS One. 2022 Dec 1;17(12):e0265212. doi: 10.1371/journal.pone.0265212. eCollection 2022.
4
Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.维莫德吉用于保存晚期眼部基底细胞癌患者的视觉功能：VISORB 试验。
Oncologist. 2021 Jul;26(7):e1240-e1249. doi: 10.1002/onco.13820. Epub 2021 May 31.
5
Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.维莫德吉新辅助治疗眼周基底细胞癌
Am J Ophthalmol Case Rep. 2020 May 23;19:100755. doi: 10.1016/j.ajoc.2020.100755. eCollection 2020 Sep.
6
Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.一项开放标签试验中眼周局部晚期基底细胞癌患者接受维莫德吉治疗的结局。
JAMA Ophthalmol. 2020 Jul 1;138(7):749-755. doi: 10.1001/jamaophthalmol.2020.1539.
7
Periocular basal cell carcinoma - clinical perspectives.眼周基底细胞癌——临床视角
Oncol Rev. 2020 Apr 30;14(1):420. doi: 10.4081/oncol.2020.420. eCollection 2020 Feb 18.
8
Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib.基底细胞癌：多模式治疗及新辅助维莫德吉的作用
Autops Case Rep. 2019 Sep 27;9(4):e2019116. doi: 10.4322/acr.2019.116. eCollection 2019 Oct-Dec.
9
[Young male patient with unusual space-occupying lesion of the lower eyelid].[患有下眼睑罕见占位性病变的年轻男性患者]
Ophthalmologe. 2020 Jan;117(1):73-77. doi: 10.1007/s00347-019-00948-y.
10
Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.维莫德吉治疗局部晚期眼周和眼眶基底细胞癌：15例连续病例回顾
Plast Reconstr Surg Glob Open. 2017 Jul 21;5(7):e1424. doi: 10.1097/GOX.0000000000001424. eCollection 2017 Jul.
本文引用的文献
1
Oral hedgehog-pathway inhibitors for basal-cell carcinoma.用于基底细胞癌的口服刺猬信号通路抑制剂
N Engl J Med. 2012 Jun 7;366(23):2225-6. doi: 10.1056/NEJMe1202170.
2
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.抑制基底细胞痣综合征患者的 hedgehog 通路。
N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.
3
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.维莫德吉治疗晚期基底细胞癌的疗效和安全性。
N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713.
4
Risk factors for orbital exenteration in periocular Basal cell carcinoma.眼周基底细胞癌行眶内容剜除术的风险因素。
Am J Ophthalmol. 2012 Feb;153(2):238-241.e1. doi: 10.1016/j.ajo.2011.08.004. Epub 2011 Oct 6.
5
Orbital invasion by periocular basal cell carcinoma.眼周基底细胞癌的眼眶侵犯
Ophthalmology. 2005 Apr;112(4):717-23. doi: 10.1016/j.ophtha.2004.11.036.
Zotero 插件